According to Vaxart's latest financial reports the company's current revenue (TTM) is $9.1 M. In 2022 the company made a revenue of $0.1 M a decrease over the years 2021 revenue that were of $0.89 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $9.1 M | 8408.41% |
2022 | $0.1 M | -88% |
2021 | $0.89 M | -77.95% |
2020 | $4.04 M | -58.97% |
2019 | $9.86 M | 137.12% |
2018 | $4.15 M | -46.68% |
2017 | $7.8 M | -19.59% |
2016 | $9.7 M | -27.61% |
2015 | $13.4 M | -74.48% |
2014 | $52.5 M | -0.1% |
2013 | $52.55 M | 327.9% |
2012 | $12.28 M | -17.23% |
2011 | $14.83 M | -57.61% |
2010 | $35 M | 233.73% |
2009 | $10.48 M | |
2006 | $89.86 M | -9.83% |
2005 | $99.66 M | -44.56% |
2004 | $0.17 B | 1.81% |
2003 | $0.17 B | -9.9% |
2002 | $0.19 B | -16.55% |
2001 | $0.23 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | 1,532.03% | ๐บ๐ธ USA |